Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Chief Financial Officer | September 02, 2025 | September 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date September 02, 2025 · Filed September 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares with a nominal value of GBP0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-09-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-09-02 · Sale · Disposed 96,000 · Balance 0 F1: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer. F2: The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs. F3: The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F4: The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.
F2: The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs.
F3: The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
F4: The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2025 Filed Sep 3, 2025 17:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleOrdinary Shares with a nominal value of GBP0.001 per share | 96,000 | $0.01 | $950.40 |
DisclosureSEC source: 0001104659-25-087085 · tm2525128d1_4seq1.xml · nonDerivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer. F2 · shares: The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs. F3 · price: The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F4 · balance_after: The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 17:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 565,416 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004524 · tm243270-7_4seq1.xml · derivative · entry 2 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,416 Underlying: Ordinary Shares · 565,416 shares Expires 2034-01-15 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 17:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,544,432 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001104659-24-004524 · tm243270-7_4seq1.xml · derivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,544,432 Underlying: Ordinary Shares · 2,544,432 shares Expires 2034-01-15 F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 21:04 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 193,728 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004372 · tm231655-12_4seq1.xml · derivative · entry 3 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,728 Underlying: Ordinary Shares · 193,728 shares Expires 2033-01-17 F5 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 21:04 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 314,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004372 · tm231655-12_4seq1.xml · derivative · entry 2 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,256 Underlying: Ordinary Shares · 314,256 shares Expires 2033-01-17 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 21:04 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,407,072 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001104659-23-004372 · tm231655-12_4seq1.xml · derivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,072 Underlying: Ordinary Shares · 1,407,072 shares Expires 2033-01-17 F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | PurchaseOrdinary Shares with a nominal value of GBP0.001 per share | 39,000 | $0.29 | $11,325.60 |
DisclosureSEC source: 0001104659-22-064008 · tm2216620-1_4seq1.xml · nonDerivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. F2 · shares: The 39,000 ordinary shares reported in Column 4 are represented by 6,500 ADSs. F3 · price: The price reported in Column 4 of $0.2904 per ordinary share is derived from the purchase price paid on May 20, 2022 of $1.7423 per ADS divided by six. F4 · balance_after: The 96,000 ordinary shares reported in Column 5 include 57,000 ordinary shares represented by 9,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 21:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 314,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-004154 · tm221700-7_4seq1.xml · derivative · entry 2 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,256 Underlying: Ordinary Shares · 314,256 shares Expires 2032-01-12 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 21:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,407,072 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-22-004154 · tm221700-7_4seq1.xml · derivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,072 Underlying: Ordinary Shares · 1,407,072 shares Expires 2032-01-12 F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026. Read SEC document |
| January 11, 2021 Filed Jan 11, 2021 21:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 242,712 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-003134 · tm212800-6_4seq1.xml · derivative · entry 2 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,712 Underlying: Ordinary Shares · 242,712 shares Expires 2031-01-11 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025. Read SEC document |
| January 11, 2021 Filed Jan 11, 2021 21:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,086,816 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-21-003134 · tm212800-6_4seq1.xml · derivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,086,816 Underlying: Ordinary Shares · 1,086,816 shares Expires 2031-01-11 F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | PurchaseOrdinary Shares with a nominal value of GBP0.001 per share | 24,000 | $0.69 | $16,550.40 |
DisclosureSEC source: 0001104659-20-136481 · tm2038497-2_4seq1.xml · nonDerivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. F2 · shares: The 24,000 ordinary shares reported in Column 4 are represented by 4,000 ADSs. F3 · price: The price reported in Column 4 of $0.6896 per ordinary share is derived from the purchase price paid on December 14, 2020 of $4.1375 per ADS divided by six. F4 · balance_after: The 57,000 ordinary shares reported in Column 5 include 33,000 ordinary shares represented by 5,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood. Read SEC document |
| June 29, 2020 Filed Jun 30, 2020 21:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | PurchaseOrdinary Shares with a nominal value of GBP0.001 per share | 33,000 | $1.62 | $53,460.00 |
DisclosureSEC source: 0001104659-20-079248 · a4.xml · nonDerivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. F2 · shares: The 33,000 ordinary shares reported in Column 4 are represented by 5,500 ADSs. F3 · price: The price reported in Column 4 of $1.62 per ordinary share is derived from the purchase price paid on June 29, 2020 of $9.7497 per ADS divided by six. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 19:06 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 565,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-042012 · a4.xml · derivative · entry 2 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,000 Underlying: Ordinary Shares · 565,000 shares Expires 2030-04-01 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 141,250 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in annual installments of 141,250 Ordinary Shares on the first of each April from April 1, 2022 through April 1, 2024. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 19:06 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,500,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001104659-20-042012 · a4.xml · derivative · entry 1 Wood Gavin · CIK 0001577539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Ordinary Shares · 2,500,000 shares Expires 2030-04-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.36 based on an exchange rate of U.S.$1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 625,000 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in monthly installments of 52,080 Ordinary Shares on the first of each month from May 1, 2021 through March 1, 2024 and 52,200 Ordinary Shares on April 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.